Safety of atovaquone-proguanil during pregnancy | Zendy

Romana Mayer | Zendy; Kathrine R. Tan | Zendy; Julie Gutman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of atovaquone-proguanil during pregnancy

Author(s) -

Romana Mayer,

Kathrine R. Tan,

Julie Gutman

Publication year - 2018

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.1093/jtm/tay138

Subject(s) - medicine , pregnancy , miscarriage , small for gestational age , obstetrics , low birth weight , adverse effect , malaria , live birth , pediatrics , premature birth , birth weight , gestational age , genetics , immunology , biology

Malaria during pregnancy increases the risk of maternal and foetal complications. There are very limited options for prophylaxis in pregnant travellers. Atovaquone-Proguanil (AP or Malarone®) is an effective and well-tolerated antimalarial medication, but is not recommended for use in pregnancy due to limited data on safety. Passively reported adverse event data may provide additional information on the safety of AP during pregnancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research